• 1
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637645.
  • 2
    Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxyliv acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem. 1996;39:323338.
  • 3
    Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin-II receptor antagonist. Eur J Pharmacol. 1995;285:181188.
  • 4
    Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin-II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001;41:515527.
  • 5
    Israili ZH. Clinical pharmacokinetics of angiotensin-II (AT1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(suppl 1):S73S86.
  • 6
    Masonson HN, Punzi HA, Neutel JM, et al. CS-866 (angiotensin-II receptor antagonist): a double-blind study using ambulatory blood pressure monitoring in hypertensive patients [abstract]. Am J Hypertens. 1998;11:77A.
  • 7
    Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens. 1998;11:445453.
  • 8
    Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12:414417.
  • 9
    Mallion JM, Siche JP, Lacourcière Y, for the Telmisartan Blood Pressure Monitoring Group. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657664.
  • 10
    Diamant M, Idema RN, Vincent HH. The use of Fourier analysis in the calculation of trough-to-peak ratio from ambulatory blood pressure measurements. J Hum Hypertens. 1998;12:6167.
  • 11
    Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75:383386.
  • 12
    Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil. A new generation angiotensin II antagonist, in comparison with losartan. Blood Press. 1998;7:5359.
  • 13
    Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther. 1998;20:398409.
  • 14
    Marino MR, Langenbacher K, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol. 1998;38:246255.
  • 15
    Ohtawa M, Takayama F, Saitoh K, et al. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290297.
  • 16
    Muller P, Flesch G, De Gasparo M, et al. Pharmacokinetics and pharmacodynamics effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol. 1997;52:441449.
  • 17
    Leenen FH, Fourney A, Notman G, et al. Persistence of antihypertensive effect after “missed doses” of calcium antagonist with long (amlodipine) vs. short (diltiazem) elimination of half-life. Br J Clin Pharmacol. 1996;41:8388.
  • 18
    Lee JY, Kusek JW, Greene PG, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. 1996;9:719725.
  • 19
    Staessen JA, Beilin L, Parati G, et al. Task force IV: clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. Blood Press Monit. 1999;4:319331.
  • 20
    Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hypertens. 1999;12:11811187.
  • 21
    Monterroso VH, Rodriguez Chavez V, Carbajal ET, et al. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators. Adv Ther. 2000;17:117131.
  • 22
    Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000;16:11231132.
  • 23
    MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease; part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765774.
  • 24
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 25
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412419.
  • 26
    Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest. 1969;56:4352.
  • 27
    Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke (The Framingham Study). JAMA. 1970;214:301310.
  • 28
    Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis. 1974;17:524.
  • 29
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:32553264.
  • 30
    Kannel WB. Epidemiology of essential hypertension: the Framingham experience. Proc R Coll Physicians. 1991;21:273287.
  • 31
    Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865872.
  • 32
    Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11:11331137.
  • 33
    Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:24132446.
  • 34
    Mancia G, Dell'Oro R, Turri C, et al. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol. 1999;84:28S34S.
  • 35
    Elliot HL. Trough:peak ratio and twenty-four hour blood pressure control. J Hypertens. 1994;12(suppl 5):29S33S.
  • 36
    Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf. 1999;21:2333.
  • 37
    Wiklund I, Halling K, Ryden-Bergsten T, et al. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press. 1997;6:357364.